Journal of Clinical Endocrinology & Metabolism, Vol 71, 918-922, Copyright © 1990 by Endocrine Society

ARTICLES

Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization

Y Gonen, H Balakier, W Powell and RF Casper
Department of Obstetrics and Gynecology, University of Toronto, Ontario, Canada.

In spontaneous cycles both LH and FSH are secreted in a surge at midcycle. In in vitro fertilization (IVF) cycles, hCG administration results in elevation of LH-like activity only. The objective of this study was to compare the effectiveness of a single midcycle dose of GnRH agonist with hCG on follicular maturation. Eighteen IVF cycles in 14 women were randomized to receive either 0.5 mg leuprolide acetate or 5000 IU hCG at midcycle. Both groups underwent identical ovarian stimulation and cycle monitoring. On the day of GnRH agonist or hCG administration, estradiol concentrations and the number of follicles 1.5 cm or larger were the same in both groups. Mean serum LH and FSH levels were elevated for 34 h after GnRH agonist administration. In contrast, mean serum hCG levels were elevated for approximately 6 days after the administration of hCG, and serum FSH levels did not change. Mean luteal phase serum estradiol concentrations were lower in the GnRH agonist group than in the hCG group (P less than 0.02). No differences were observed in mean serum progesterone or PRL during the luteal phase or in the length of the luteal phase in the two groups. The mean number of oocytes retrieved and embryo number and quality did not differ between the two groups. Three of nine GnRH agonist cycles and none of nine hCG cycles resulted in clinical pregnancy (P = 0.1). The results of this study indicate that GnRH agonist is able to simulate a midcycle surge of gonadotropins, leading to follicular maturation and pregnancy. Further work is needed to determine whether there is any clinical advantage of GnRH agonist over hCG administration with regard to pregnancy rates.

This article has been cited by other articles:

				S. Dias, R. McNamee, and A. Vail Evidence of improving quality of reporting of randomized controlled trials in subfertility Hum. Reprod., October 1, 2006; 21(10): 2617 - 2627. [Abstract] [Full Text] [PDF]

				C. Y. Andersen, P. Humaidan, H. B. Ejdrup, L. Bungum, M.L. Grondahl, and L.G. Westergaard Hormonal characteristics of follicular fluid from women receiving either GnRH agonist or hCG for ovulation induction Hum. Reprod., August 1, 2006; 21(8): 2126 - 2130. [Abstract] [Full Text] [PDF]

				N. S. Macklon, R. L. Stouffer, L. C. Giudice, and B. C. J. M. Fauser The Science behind 25 Years of Ovarian Stimulation for in Vitro Fertilization Endocr. Rev., April 1, 2006; 27(2): 170 - 207. [Abstract] [Full Text] [PDF]

				G. Griesinger, K. Diedrich, P. Devroey, and E.M. Kolibianakis GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis Hum. Reprod. Update, March 1, 2006; 12(2): 159 - 168. [Abstract] [Full Text] [PDF]

				E.M. Kolibianakis, A. Schultze-Mosgau, A. Schroer, A. van Steirteghem, P. Devroey, K. Diedrich, and G. Griesinger A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists Hum. Reprod., October 1, 2005; 20(10): 2887 - 2892. [Abstract] [Full Text] [PDF]

				P. Humaidan, H. Ejdrup Bredkjaer, L. Bungum, M. Bungum, M.L. Grondahl, L. Westergaard, and C. Yding Andersen GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study Hum. Reprod., May 1, 2005; 20(5): 1213 - 1220. [Abstract] [Full Text] [PDF]

				N. G. M. Beckers, N. S. Macklon, M. J. Eijkemans, M. Ludwig, R. E. Felberbaum, K. Diedrich, S. Bustion, E. Loumaye, and B. C. J. M. Fauser Nonsupplemented Luteal Phase Characteristics after the Administration of Recombinant Human Chorionic Gonadotropin, Recombinant Luteinizing Hormone, or Gonadotropin-Releasing Hormone (GnRH) Agonist to Induce Final Oocyte Maturation in in Vitro Fertilization Patients after Ovarian Stimulation with Recombinant Follicle-Stimulating Hormone and GnRH Antagonist Cotreatment J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4186 - 4192. [Abstract] [Full Text] [PDF]

				B. C. Fauser, D. de Jong, F. Olivennes, H. Wramsby, C. Tay, J. Itskovitz-Eldor, and H. G. van Hooren Endocrine Profiles after Triggering of Final Oocyte Maturation with GnRH Agonist after Cotreatment with the GnRH Antagonist Ganirelix during Ovarian Hyperstimulation for in Vitro Fertilization J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 709 - 715. [Abstract] [Full Text] [PDF]

				J. Itskovitz-Eldor, S. Kol, and B. Mannaerts Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: Short communication Hum. Reprod., September 1, 2000; 15(9): 1965 - 1968. [Abstract] [Full Text] [PDF]

				A.P. Ferraretti, L. Gianaroli, C. Magli, D. Fortini, H.A. Selman, and E. Feliciani Elective cryopreservation of all pronucleate embryos in women at risk of ovarian hyperstimulation syndrome: efficiency and safety Hum. Reprod., June 1, 1999; 14(6): 1457 - 1460. [Abstract] [Full Text] [PDF]